3SBio : 2024 Annual Results

2024 Annual Results Presentation

26 March, 2025

Agenda

3

16.5%

YOY

17.9%

YOY

GPM：86.0%

34.9%

YOY

18.8%

YOY

8.1Bn

Bn RMB

Bn RMB

Bn RMB

Bn RMB

Bn RMB

9.1

8.2

8.1

2.3

7.8

2.1

2020 2021 2022 2023 2024

2020 2021 2022 2023 2024

2020 2021 2022 2023 2024

2020 2021 2022 2023 2024

2020 2021 2022 2023 2024

5

2024年业务里程碑

• • 《Clinical Guidelines • for Renal Transplantation 》 recommend TPIAO ® for Renal Transplantation TCP

• • Studies of Inetetamab were selected for the 2024- year ASCO TPIAO ® Phase III Study of CLDT achieved Primary Endpoint

• • TPIAO ® NDA of CLDT was accepted by CDE

• • Studies of Inetetamab were selected in ESMO 2024，reflecting its efficacy and safety in BC neoadjuvant treatment

  • • Te Ai Sheng ® approved to launch

• • Cooperation with Haihe Biopharma in respect of commercialization rights of Paclitaxel Oral Solution in Mainland China and HK.

• • Cooperation with Sunshine Lake Pharma in respect of commercialization rights of Clifutinib in Mainland China.

• • strategic cooperation with NK Celltech

• • Participated in the A+ financing for C-ray

2月

4月

6月

8月

10月

12月

1月

3月

5月

7月

9月

11月

1月

• • Tacrolimus Cream NDA approved

• • Anti-IL-5 Ab (610) Ph II study of Eosinophilic asthma achieved Primary Endpoint

• • Anti-IL-4R Ab (611) Ph III study of Adult AD complete FP enrollment

• • Anti-IL-1β Ab (613) Ph III study of AG complete FP enrollment

• • Anti-IL-4R Ab (611) Ph II study of CRSwNP achieved Primary Endpoint

• • Anti-IL-17 Ab (608) Ph III study of PsO achieved Primary Endpoint

• • Mandi won No.1 among Tmall JD and Tiktok in "Double 11" festival "

• • Winlevi® complete all patient enrollmeng in the Ph III bridging trial of Acne

2020

2021

2022

2023

2024

1.数据来源： IQVIA ，Markets scale includes rhTPO ,IL-11,TPO-RA and Romiplostim

Class B（Oral TPO-RA）

Class C（Romiplostim）

8

Competitive Advantage

• ✓ The only specific ascending plate drug with

  CIT indication;

• ✓ Guideline recommend 1A, evidence-based

• ✓ Fast onset time, efficacy reflect in 3-7 days

• ✓ No liver toxicity, no risk of bone marrow fibrosis, no risk of thrombosis, high safety

• ✓ Daily dosage, facilitates Hematological indicators monitoring and adjustment of dosage

2005

2011

2022

2023

2024.04

2025E

• • Chemotherapy composed of multiple cytotoxic components, which may lead to cumulative hematological toxicities;

• • Targeted therapy with small molecule tyrosine kinase inhibitors causes 20% incidence of TCP ；some of them will high the rate up to 54%

• • ADC therapy moved to initial treatment plan in Clinical Guidance, lead to a higher incidence of TCP

• • PD-1/PD-L1 inhibitors have a probability of about 10% to cause grade 1-4 TCP